TrialSignal
Clinical trial intelligence report
Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01266213
Status
UNKNOWN
Phase
Phase II
Sponsor
Samsung Medical Center
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates the efficacy of high-dose Fulvestrant combined with Goserelin compared to Anastrozole with Goserelin and Goserelin alone in premenopausal women with recurrent or metastatic hormone receptor-positive breast cancer who have previously been treated with Tamoxifen. The study aims to determine the best treatment approach for this patient population.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01266213
Indication
Metastatic Breast Cancer
Modality
small molecule
Target
Estrogen Receptor Positive Tumor
Intervention
Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.